Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

4.23
+0.440011.61%
Pre-market: 3.93-0.3000-7.09%06:45 EDT
Volume:2.48M
Turnover:10.03M
Market Cap:61.57M
PE:-0.34
High:4.29
Open:3.76
Low:3.76
Close:3.79
52wk High:13.36
52wk Low:1.17
Shares:14.56M
Float Shares:5.51M
Volume Ratio:0.93
T/O Rate:44.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.2842
EPS(LYR):-23.5105
ROE:-1766.94%
ROA:-68.72%
PB:-0.57
PE(LYR):-0.18

Loading ...

BioXcel Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

BUZZ-U.S. STOCKS ON THE MOVE-CrowdStrike, Nvidia, EchoStar

Reuters
·
Aug 28

BioXcel Therapeutics Shares Down 6% After Co Reports Late-Stage Data for Agitation Drug

THOMSON REUTERS
·
Aug 27

Update -- BioXcel Therapeutics Announces Serenity at-Home Pivotal Phase 3 Safety Trial Met Its Primary Endpoint in Support of Snda Submission for Label Expansion of Igalmi®

THOMSON REUTERS
·
Aug 27

BioXcel Therapeutics Shares Resume Trading Premarket After Co Reports Late-Stage Data for Agitation Drug in at-Home Setting, Last up About 10%

THOMSON REUTERS
·
Aug 27

BioXcel's agitation drug meets main goal in at-home study

Reuters
·
Aug 27

BioXcel Therapeutics Inc - Bxcl501 120 Mcg Dose Well-Tolerated in Outpatient Setting

THOMSON REUTERS
·
Aug 27

BioXcel Therapeutics Inc - Serenity at-Home Phase 3 Trial Meets Primary Endpoint

THOMSON REUTERS
·
Aug 27

BioXcel Therapeutics Inc - Plans Snda Submission for Bxcl501 in Q1 2026

THOMSON REUTERS
·
Aug 27

BRIEF-BioXcel Therapeutics To Announce Topline Results From Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia On August 27, 2025

Reuters
·
Aug 27

BioXcel Therapeutics to Announce Topline Results From Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia on August 27, 2025

THOMSON REUTERS
·
Aug 27

BioXcel Therapeutics Announces Database Lock In Serenity At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia

Reuters
·
Aug 19

BioXcel Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 19

BioXcel Therapeutics Announces Database Lock in Serenity at-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia

THOMSON REUTERS
·
Aug 19

BioXcel Therapeutics Inc - Topline Results Expected in August

THOMSON REUTERS
·
Aug 19

BioXcel Therapeutics Inc. Announces ATM Program for Sale of Up to $80 Million in Common Stock

Reuters
·
Aug 19

BUZZ-U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx

Reuters
·
Aug 18

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?

Benzinga
·
Aug 18

BRIEF-BioXcel Therapeutics Announces Positive FDA Pre-SNDA Meeting Comments For SNDA Submission For Bxcl501 In Agitation Associated With Bipolar Disorders Or Schizophrenia

Reuters
·
Aug 18

BUZZ-BioXcel jumps after positive FDA feedback on Alzheimer's-linked drug application

Reuters
·
Aug 18